stockportfolio.pro
Veracyte, Inc. (VCYT)
Healthcare · Diagnostics & Research · NasdaqGM
Veracyte, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.08M | $71.95M | $92.01M | $120.37M | $117.48M | $219.51M | $296.54M | $361.05M | $445.76M | $517.14M |
| Gross profit | $39.62M | $43.76M | $58.93M | $84.29M | — | — | $175.68M | $229.68M | $298.14M | $362.53M |
| Net income | $0 | $0 | $-23.00M | $-12.60M | $-34.91M | $-75.56M | $-36.56M | $-74.40M | $24.14M | $66.35M |
| Net margin | 0.0% | 0.0% | -25.0% | -10.5% | -29.7% | -34.4% | -12.3% | -20.6% | 5.4% | 12.8% |
Source: Veracyte, Inc. SEC filings (10-K). 15 years of history available in the interactive view.
What growth is priced into VCYT stock?
At today's market cap of $3.87B, Veracyte, Inc. is priced for free-cash-flow growth of about 13.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $126.63M from the FY ending 2025-12-31). For comparison, revenue 34.5%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 15 years of Veracyte, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track VCYT in your portfolio →
Veracyte, Inc. financial history by metric
About Veracyte, Inc.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Veracyte, Inc. — frequently asked questions
What is Veracyte, Inc.'s revenue?
Veracyte, Inc. (VCYT) reported revenue of $517.14M for fiscal year 2025, up 16.0% from the prior year, according to its SEC filings.
Is Veracyte, Inc. profitable?
Yes. VCYT earned net income of $66.35M in fiscal 2025, a net margin of 12.8%.
What is VCYT's P/E ratio?
Veracyte, Inc. trades at a price-to-earnings ratio of about 44.9 based on the latest data in our nightly-refreshed cache.
How fast is Veracyte, Inc. growing?
VCYT's revenue grew at roughly 34.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Veracyte, Inc. have?
As of fiscal year 2025, VCYT carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Veracyte, Inc.'s gross margin?
VCYT's gross margin was 70.1% in fiscal 2025 — gross profit of $362.53M on revenue of $517.14M.
What is Veracyte, Inc.'s market cap?
Veracyte, Inc. (VCYT) has a market capitalization of about $3.87B, based on the latest data in our nightly-refreshed cache.
When does Veracyte, Inc.'s fiscal year end?
VCYT's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into VCYT stock?
At today's market cap of $3.87B, Veracyte, Inc. is priced for free-cash-flow growth of about 13.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $126.63M from the FY ending 2025-12-31). For comparison, revenue 34.5%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Veracyte, Inc.'s official SEC filings (10-K and 10-Q), covering 15 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.